Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969461 | 0.84 | LMNA (0.48) | KMT2AMEN1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL4013745 | 0.84 | KMT2A (0.49) | KMT2AMEN1ALDH1A1SMN1; SMN2ACACB | |
| SCHEMBL6787347 | 0.84 | ALOX15 (0.49) | KMT2ARAB9ANPSR1MEN1HTT | |
| SCHEMBL8185790 | 0.83 | HTT (0.50) | KMT2ARAB9ANPSR1MEN1HTT | |
| SCHEMBL8881032 | 0.82 | ESR1 (0.54) | KMT2ACA1CA2ALDH1A1CYP1A2 | |
| SCHEMBL1564938 | 0.82 | CYP1A2 (0.50) | KMT2ARAB9ANPSR1MEN1ALDH1A1 | |
| SCHEMBL6844006 | 0.82 | CYP1A2 (0.56) | RAB9ANPSR1CA1CA2ALDH1A1 | |
| SCHEMBL8933321 | 0.82 | ALDH1A1 (0.47) | KMT2ARAB9ANPSR1MEN1HTT | |
| SCHEMBL4776154 | 0.82 | L3MBTL1 (0.45) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4013605 | 0.82 | L3MBTL1 (0.46) | KMT2ARAB9AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115175907-A | Substituted piperazine derivatives useful as T cell activators | 百时美施贵宝公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| WO-2021133749-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | disclosed |
| CN-112469722-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3406602-B1 | 1-SULFONAMIDO-4-ARYLOXY COMPOUND, AND PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | UNIV CHINA PHARMA (CN) | 2020-03-04 | — | — | EP | disclosed |
| WO-2020020097-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEIGENE, LTD. (KY) | 2020-01-30 | — | — | WO | disclosed |
| US-10442759-B2 | 1-sulfonamido-4-aryloxy compounds, and preparation method and medicinal application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2019-10-15 | — | — | US | disclosed |
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-05-21 | — | — | US | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1001777-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| WO-1999004796-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-04 | — | — | WO | disclosed |
| US-5679852-A | Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5676923-A | SOLUBLE, STABLE, ORGAN-SPECIFIC NUCLEAR MAGNETIC RESONANCE CONTRAST AGENT | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-14 | — | — | US | disclosed |
| US-5676926-A | Process for the production of DTPA-tetraesters of terminal carboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-10-14 | — | — | US | disclosed |
| US-5514810-A | Process for the production of DTPA-tetraesters of terminal carboxylic acids | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-05-07 | — | — | US | disclosed |
| WO-1994021255-A1 | SIX-MEMBERED RING FUSED IMIDAZOLES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5334598-A | Have endothelin antagonist activity; useful in treating cardiovascular disorders, hypertension, inflammatory diseases and asthma | MERCK & CO., INC. (US) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | KMT2A 2009/4885RAB9A 1988/4885NPSR1 148/4885 |
| US-10442759-B2 | 1-sulfonamido-4-aryloxy compounds, and preparation method and medicinal application thereof | KEAP1, NFE2L2, QSOX1 | KMT2A 2633/4885RAB9A 2556/4885NPSR1 443/4885 |
| US-20230118629-A1 | SUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | KMT2A 1560/4885RAB9A 689/4885NPSR1 2032/4885 |
| US-10294221-B2 | 1, 3, 4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GSS | KMT2A 2258/4885RAB9A 2330/4885NPSR1 2256/4885 |
| US-12454531-B2 | Substituted piperazine derivatives useful as T cell activators | DGKZ, DGKA, DGKG | KMT2A 1560/4885RAB9A 689/4885NPSR1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.